


## (R)-Merimepodib

<b>Cat. No.:</b>	HY-13986A		
<b>Molecular Formula:</b>	C <sub>23</sub> H <sub>24</sub> N <sub>4</sub> O <sub>6</sub>		
<b>Molecular Weight:</b>	452.46		
<b>Target:</b>	Others		
<b>Pathway:</b>	Others		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (221.01 mM; Need ultrasonic)

Concentration	Solvent	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.2101 mL	11.0507 mL	22.1014 mL
	5 mM		0.4420 mL	2.2101 mL	4.4203 mL
	10 mM		0.2210 mL	1.1051 mL	2.2101 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

(R)-Merimepodib is the inactive isomer of Merimepodib (HY-13986), and can be used as an experimental control. Merimepodib (VX-497) is a noncompetitive and oral inhibitor of inosine monophosphate dehydrogenase (IMPDH) with broad spectrum antiviral activities.

### REFERENCES

- [1]. Jain J, et al. VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. *J Pharm Sci.* 2001 May;90(5):625-37.
- [2]. Decker CJ, et al. The novel IMPDH inhibitor VX-497 prolongs skin graft survival and improves graft versus host disease in mice. *Drugs Exp Clin Res.* 2001;27(3):89-95.
- [3]. Markland W, et al. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. *Antimicrob Agents Chemother.* 2000 Apr;44(4):859-66.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA